- Home
- KOD vs BL Comparison
KOD vs BL Comparison
Compare KOD & BL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KOD | BL |
|---|---|---|
| Founded | 2009 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.2B |
| IPO Year | 2018 | 2016 |
Fundamental Metrics
Financial Performance| Metric | KOD | BL |
|---|---|---|
| Price | $45.52 | $31.59 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 13 |
| Target Price | $35.43 | ★ $56.62 |
| AVG Volume (30 Days) | ★ 1.1M | 991.7K |
| Earning Date | 05-13-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.39 |
| Revenue | N/A | ★ $177,031,000.00 |
| Revenue This Year | N/A | $12.62 |
| Revenue Next Year | N/A | $10.90 |
| P/E Ratio | ★ N/A | $79.05 |
| Revenue Growth | N/A | ★ 43.78 |
| 52 Week Low | $3.33 | $28.78 |
| 52 Week High | $47.84 | $59.57 |
Technical Indicators
Market Signals| Indicator | KOD | BL |
|---|---|---|
| Relative Strength Index (RSI) | 63.05 | 41.44 |
| Support Level | $21.82 | $29.67 |
| Resistance Level | $45.60 | $34.06 |
| Average True Range (ATR) | 3.11 | 1.57 |
| MACD | -0.39 | 0.06 |
| Stochastic Oscillator | 71.41 | 50.57 |
Price Performance
Historical ComparisonAbout KOD Kodiak Sciences Inc
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
About BL BlackLine Inc.
BlackLine Inc is engaged in providing financial accounting close solutions delivered as Software as a Service (SaaS). The Company's solutions enable its customers to address various aspects of their critical processes, including financial close & consolidation, intercompany accounting, and invoice-to-cash. The majority of the revenue of the company is earned in the United States.